U.S. Surgical
This article was originally published in The Gray Sheet
Executive Summary
Eliminates 775 jobs from its Connecticut and Puerto Rico operations in a cost-cutting move, the firm says Oct. 30. Two-thirds (490) of the reductions are voluntary and affect primarily manufacturing positions, while the remaining 285 layoffs involve supervisory and managerial staff at USSC, which was recently bought by Tyco International for $3.3 bil. ("The Gray Sheet" June 1, p. 3). No cuts in the firm's sales force are made. Future reductions at USSC's non-Connecticut operations also are expected, according to the firm, which plans over the next 15 months to consolidate its Norwalk and North Haven, Connecticut, facilities in a single campus at North Haven
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.